We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


JCA and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "JCA and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Debiopharm Group™ will be presenting the ‘JCA-Mauvernay Award’ on October 10 to Doctors Yutaka Kondo from the Nagoya City University Graduate School of Medical Sciences for his basic research on Targeting Epigenetics as a New Paradigm in Cancer Treatment and Junko Takita from Graduate School of Medicine, the University of Tokyo for her applied research on Identification of Molecular Therapeutic Targets for Pediatric Cancers.

Doctors Kondo and Takita will receive their Awards during the General Assembly of the 74th Annual Meeting of the Japanese Cancer Association (JCA) in Nagoya City on the following theme: ‘From collaboration to integration: Cancer research for patients’ benefit’. Dr. Kohei Miyazano, President of the JCA and Thierry Mauvernay, Delegate of the Board of Debiopharm Group, will present the trophies to both scientists.

“We are honored and proud to reward such talented scientists chosen for the high standard and potential applications of their research. We wish them both success with their work and hope they will lead to effective treatments in the years to come”, said Thierry Mauvernay, Delegate of the Board of Debiopharm Group.

Dr. Kondo explores the role of epigenetic dysregulation in cancer. Differences in tumor behavior can be explained by variations in gene expression patterns, which can be generated by epigenetic mechanisms. His research focuses on the functional impact of aberrant epigenetic mechanisms on tumorigenesis, and their potential clinical application in areas such as cancer detection, classification and therapeutic targets validation.

One of the significant causes of death among children is pediatric cancers. Dr. Takita and her group have conducted extensive studies on the molecular mechanisms of intractable pediatric cancers, including neuroblastoma, rhabdomyosarcoma, pleuropulmonary blastoma and hematological malignancies. Their recent studies have shown the differences in the molecular mechanisms underlying pediatric and adult leukemias.